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Abstract
Objectives: To determine the incidence of WHO clinical stage 3 and 4 conditions during early anti-retroviral therapy (ART) in
resource limited settings (RLS).
Design/Setting: A descriptive analysis of routine program data collected prospectively from 25 Me ´decins Sans Frontie `res
supported HIV treatment programs in eight countries between 2002 and 2010.
Subjects/Participants: 35,349 study participants with median follow-up on ART of 1.33 years (IQR 0.51–2.41).
Outcome Measures: Incidence in 100 person-years of WHO stage 3 or 4 conditions during 5 periods after ART initiation.
Diagnoses of conditions were made according to WHO criteria and relied upon clinical assessments supported by basic
laboratory investigations.
Results: The incidence of any WHO clinical stage 3 or 4 condition over 3 years was 40.02 per 100 person-years (31.77 for
stage 3 and 8.25 for stage 4). The incidence of stage 3 and 4 conditions fell by over 97% between months 0–3 and months
25–36 (77.81 to 2.40 for stage 3 and 28.70 to 0.64 for stage 4). During months 0–3 pulmonary tuberculosis was the most
common condition diagnosed in adults (incidence 22.24 per 100 person-years) and children aged 5–14 years (25.76) and
oral candidiasis was the most common in children ,5 years (25.79). Overall incidences were higher in Africa compared with
Asia (43.98 versus 12.97 for stage 3 and 8.98 versus 7.05 for stage 4 conditions, p,0.001). Pulmonary tuberculosis, weight
loss, oral and oesophageal candidiasis, chronic diarrhoea, HIV wasting syndrome and severe bacterial infections were more
common in Africa. Extra-pulmonary tuberculosis, non-tuberculous mycobacterial infection, cryptococcosis, penicilliosis and
toxoplasmosis were more common in Asia.
Conclusions: The incidence of WHO stage 3 and 4 conditions during the early period after ART initiation in RLS is high, but
greatly reduces over time. This is likely due to both the benefits of ART and deaths of the sickest patients occurring shortly
after ART initiation. Access to appropriate disease prevention tools prior to ART, and early initiation of ART, are important for
their prevention.
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Introduction
Efforts to scale up provision of anti-retroviral therapy (ART) in
resource-limited settings (RLS) have dramatically increased over
the past decade [1,2]. A vital role of such programs is diagnosis,
treatment and prevention of HIV associated conditions which
contribute significantly to morbidity and mortality in patients on
ART in RLS [2,3,4,5].
In developed countries ART reduces the incidence of HIV
associated conditions [6,7,8,9]. In RLS there is a lack of data
regarding the frequency and relative importance of common HIV
associated conditions after commencement of ART. It is also
unclear whether there are differences in disease incidence rates
between regions and age groups.
A more detailed understanding of the incidence of specific HIV
associated conditions after ART initiation will aid clinicians in
management of patients during ART and assist program planners
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0in strategic decision making and resource allocation for preven-
tion, diagnosis and treatment of these conditions. Therefore, this
study aims to describe the incidence of WHO Stage 3 and 4
conditions for three years following ART initiation in patients
attending Me ´decins Sans Frontie `res (MSF) supported treatment
programs in RLS and to examine how this is influenced by region
and age.
Methods
Ethics Statement
The Monash University Human Research Ethics Committee,
Alfred Health Human Ethics Committee, and MSF Human Ethics
committee approved the study.
Study Setting and Population
We analysed routine clinical data collected prospectively
between 2002 and 2010 from 25 MSF supported HIV treatment
programs in ten countries (Democratic Republic of Congo,
Ethiopia, India, Ivory Coast, Moldova, Myanmar, Nigeria,
Republic of Congo, Zambia, and Zimbabwe).
Adults and children who commenced ART without previously
taking antiretrovirals and could contribute at least 3 months of
follow-up data were eligible for inclusion. Patients were stratified
into the following age groups: ,5 years, 5–14 years, $15 years.
Children ,2 years of age with unknown HIV status who were
receiving ART were excluded.
HIV associated clinical conditions diagnosis and treatment
protocols, adherence counselling, patient follow-up, data collection
and monitoring, laboratory protocols, and drug procurement and
supply mechanisms were standardised across MSF programmes
[10]. Treatment sites included hospital settings and peripheral
health clinics.
Diagnoses of HIV-associated clinical conditions were usually
made according to WHO criteria for individual conditions [11] by
treating clinicians (medical doctors and clinical officers). Diagnoses
relied on clinical assessments supported by basic laboratory
investigations, including biochemistry, haematology, sputum
microscopy for acid fast bacilli (AFB) stains, India ink examination
of cerebro-spinal fluid and chest x-ray. More sophisticated
investigations such as cryptococcal antigen assay and abdominal
ultrasound were available at limited sites.
ART regimens were usually non-nucleoside reverse-transcrip-
tase inhibitor (NNRTI) based. Eligibility criteria for ART and
first-line regimens were standardized and based on WHO
guidelines [11,12]. Clinical consultations and intensive adherence
counselling sessions were provided before and during ART. Daily
co-trimoxazole prophylaxis was given to all patients with clinical
stage 2, 3 and 4 disease or those with CD4 cell count ,350 cells/
mm
3. Patients did not routinely receive prophylaxis for tubercu-
losis (TB) or Mycobacterium Avium Complex (MAC), apart from
those in Myanmar programmes where MAC prophylaxis was
generally provided for patients with CD4,50 cells/mm
3. CD4
counts were usually monitored using automated methods but HIV
viral load was not systematically monitored. All treatment was
free.
Data Collection
Information about medical history and sociodemographic
characteristics were collected at the initial consultation. Clinical
and therapeutic information, including any new HIV associated
clinical conditions, weight, and duration of follow up was recorded
at subsequent consultations. All information was collected on
standard forms and entered into FUCHIA software on site
(Follow-up and Care of HIV Infection and AIDS, Epicentre).
Analysis
Categorical variables were summarised using frequency and
percentage and analysed using a chi-square test. Continuous
variables were first tested for normality. As all were significantly
skewed they were summarised using median and inter-quartile
range (IQR) and analysed using a Wilcoxon rank-sum test.
Incidence rates were designed a priori to be reported as crude,
unadjusted rates. Incidence rates for any WHO stage 3 or 4
condition were calculated for five periods after ART initiation (0–
3, 4–6, 7–12, 13–24 and 25–36 months) by dividing the number of
occurrences of any stage 3 or 4 condition by the number of person-
years at risk, within that particular time period. Patients were
censored at death, loss to follow-up, or, where no disease event was
recorded within a particular time period, at 3, 6, 12, 24 or 36
months respectively after ART initiation. Patients missing an
appointment by $2 months were considered lost to follow-up and
censored on the day of their last visit. All incidence estimates are
conditional on patients being alive and on treatment at the
beginning of the period, and as they are crude and unadjusted,
and the groups are not independent, direct comparisons between
time-periods should be interpreted with caution. As we did not
evaluate whether incidence rates might have declined due to
deaths in the prior time period, we cannot state the degree to
which changing rates are due to the impact of ART or to the death
of severely ill persons in the prior time period.
Disease specific incidence rates were calculated for the same
time periods by dividing the number of first diagnoses of each
WHO stage 3 or 4 condition by the number of person- years at
risk. These analyses considered only the WHO stage 3 or 4
condition of interest and data was censored as described above for
any WHO stage 3 or 4 incidence.
Analyses were also performed by region (Africa and Asia) and
by age group. Data from Moldova (Eastern Europe) was excluded
from the regional analysis due to the small number of patients.
Confidence intervals were calculated for all rates.
Data were extracted from individual program FUCHIA
databases, de-identified and analysed using Stata version 12
(StataCorp, College Station, Texas, USA).
Results
Patients
A cohort of 36,664 patients initiated ART treatment. Table 1
shows the baseline characteristics of 34,749 patients who
contributed at least 3 months follow-up and were included in
the analysis. Sixty-two percent of these patients were from African
programmes and 36% were from Asian programmes. Eighty-nine
percent of patients were aged $15 years, 5% were aged 5–14
years, and 6% were aged ,5 years; there were proportionally less
adults and more children in African compared to Asian
programmes (p,0.001). The median time on ART was 1.33
years, with patients attending Asian programs followed longer
than those attending African programmes (median 1.6 years and
1.1 years, respectively, p,0.001). A larger proportion of patients
attending African sites was female (67% compared to 44%,
p,0.001). The median CD4 level at ART commencement was
higher in African patients than in Asian patients for all age-groups
(p,0.001).
A further 600 patients with 3 months follow-up from the
Moldova programme in Eastern Europe were included in all
analyses except the regional analysis. Ninety-three percent of
Incidence of WHO Stage 3 and 4 Conditions on ART
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years and 5.8% were aged ,5 years. The median time on ART
was 0.58 years, 67.8% of patients were male and the median CD4
level at ART commencement for adults was 385 (IQR: 201–575)
cells/mm
3.
Incidence of any WHO Stage 3 or 4 Conditions
During follow-up there were 19,156 diagnoses of WHO stage 3
conditions and 4,972 diagnoses of WHO Stage 4 conditions. The
overall incidence of any WHO stage 3 or 4 condition was 40.02
(95% CI 39.52, 40.53) events per 100 person-years. The overall
incidence for any WHO stage 3 condition was 31.77 (95% CI
31.32, 32.23) episodes per 100 person-years. This reduced by 97%
from 77.81 (95% CI 75.63, 80.04) episodes per 100 person-years
in the first 3 months to 2.40 (95% CI 2.24, 2.58) episodes per 100
person-years in months 25–36. The overall incidence for any
WHO stage 4 condition was 8.25 (95% CI 8.02, 8.48) episodes per
100 person-years. This reduced by 98% over the 3-year follow-up,
from 28.70 (95% CI 27.38, 30.07) episodes per 100 person-years
in the first 3 months to 0.64 (95% CI 0.56, 0.73) episodes per 100
person-years in months 25–36.
The incidence of any WHO stage 3 condition diagnosed over
follow up was similar across all age groups [Stage 3 conditions:
age,5 years –34.09 episodes per 100 person-years (95% CI 31.44,
36.90); age 5–14 years –28.46 episodes per 100 person-years (95%
CI 25.84, 31.27); age $15 years –30.59 episodes per 100 person-
years (95% CI 30.14, 31.05), p=0.24]. For WHO stage 4
conditions, the incidence in patients $15 years (8.21 episodes per
100 person-years; 95% CI 7.98, 8.45) and patients 5–14 years
(5.73 episodes per 100 person-years; 95% CI 4.59, 6.07) was
greater than that in patients ,5 years (3.73 episodes per 100
person-years; 95% CI 2.89, 4.74) (p=0.01 and 0.06 respectively).
We did not detect significant differences in the incidence of any
stage 4 condition between patients aged 5–14 years and patients
$15 years (p=0.25).
Regional differences were apparent in the overall disease
burden due to both stage 3 and stage 4 conditions. The incidence
of any WHO stage 3 condition was nearly 4 times higher in Africa
than in Asia, with 43.98 (95% CI 43.29, 44.68) and 12.97 (95% CI
12.52, 13.42) episodes per 100 person-years respectively
(p,0.001). For any WHO stage 4 condition, the overall incidence
was 8.98 (95% CI 8.67, 9.30) and 7.05 (95% CI 6.73, 7.39)
diagnoses per 100 person-years in Africa and Asia, respectively
(p,0.001).
Disease Specific Incidence
Tables 2 and 3 show the incidence over 3 years follow-up for
new WHO stage 3 and stage 4 conditions. The maximum
incidence for each stage 3 and stage 4 condition occurred during
months 0–3 and decreased over time. Of the WHO stage 3
conditions, oral candidiasis and pulmonary TB had the highest
initial incidence at 22.07 (95% CI 20.92, 23.28) and 21.96 (95%
CI 20.81, 23.17) episodes per 100 person-years, respectively. The
incidence of these conditions fell by 91% and 87%, respectively, by
3 years of follow-up. For the remaining stage 3 conditions shown,
the reduction in disease specific incidence during follow-up ranged
from 82% for other severe bacterial infections and weight loss
.10% of body weight to 93% for unexplained anaemia,
neutropenia or thrombocytopenia. Of the WHO stage 4
conditions, extra-pulmonary TB and candidiasis of the oesopha-
gus, trachea, bronchi or lungs had the highest initial incidence, at
5.30 (95% CI 4.75, 5.90) and 4.67 (95% CI 4.16, 5.25) episodes
per 100 person-years during months 0–3, respectively (Table 3).
The incidence of these conditions fell by 82% and 92%,
respectively, by 3 years of follow-up. For the remaining WHO
stage 4 conditions shown, the reduction in disease specific
incidence during follow-up ranged from 82% for mucocutaneous
herpes simplex infection to 97% for nontuberculous mycobacterial
infection and Pneumocystis jiroveci pneumonia.
Regional Differences in Disease Specific Incidence
The disease specific incidence of individual WHO stage 3
conditions in months 0–3 was higher in Africa than in Asia for
all conditions except oral hairy leucoplakia (Table 4). In Africa,
pulmonary TB had the highest incidence of all WHO stage 3
conditions and this was 3 times greater than the incidence in
Asia, with 30.45 (95% CI 28.68, 32.33) compared to 9.90 (95%
CI 8.73, 11.23) episodes per 100 person-years in months 0–3.
The incidence of oral candidiasis and weight loss .10% of
body weight were also high in Africa with 29.84 (95% CI
28.09, 31.70) and 11.78 (95% CI 10.71, 12.96) episodes per 100
person- years in months 0–3, respectively. In Asia, oral
candidiasis had the highest incidence of all WHO stage 3
conditions, with 10.32 (95% CI 9.12, 11.67) episodes per 100
person-years in months 0–3. The incidence of oral hairy
Table 1. Characteristics of study participants.
Overall Africa Asia p value (Africa vs. Asia)
Number of participants (%) 34,749 (100) 21, 643 (62.3) 12,506 (36.0)
Median years of follow-up (IQR) 1.33 (0.51–2.41) 1.09 (0.41–2.38) 1.60 (0.83–2.48) ,0.001
Male Sex (%) 14,594 (42) 7,207 (33.3) 6,978 (55.8) ,0.001
Median Age (years) (IQR) 32.9 (25.7–39.2) 33.2 (25.3–40.7) 32 (26.8–37.7) ,0.001
Number of patients $15 years (%) 30,803 (88.6) 18,699 (86.4) 11,543 (92.3) ,0.001
Number of patients 5–14 years (%) 1,813 (5.2) 1,234 (5.7) 575 (4.6) ,0.001
Number of patients ,5 years (%) 2,133 (6.2) 1,710 (7.9) 388 (3.1) ,0.001
Median CD4 value at ART commencement (cells/mm3) (IQR)
Patients ,5 years (n=1999) 374 (179, 585) 568.5 (358, 981) 323 (163, 511) ,0.001
Patients 5–14 years (n=1720) 182.5 (53.5, 366.5) 459 (177, 643) 153 (48, 272.5) ,0.001
Patients $15 (n=26774) 124 (86, 172) 137 (98, 189) 103 (37–195) ,0.001
doi:10.1371/journal.pone.0052019.t001
Incidence of WHO Stage 3 and 4 Conditions on ART
PLOS ONE | www.plosone.org 3 December 2012 | Volume 7 | Issue 12 | e52019leucoplakia was also high in Asia, with 9.41 (95% CI 8.27,
10.71) episodes per 100 person-years in months 0–3.
The disease specific incidence of WHO stage 4 conditions in
months 0–3 was higher in Asia for 60% of conditions (Table 5).
These included extra-pulmonary TB, non tuberculous mycobac-
terial infections, toxoplasmosis, pneumocystis jiroveci pneumonia and
cryptococcosis. Penicilliosis occurred exclusively in Asia. HIV
wasting syndrome, candidiasis of the oesophagus, trachea, bronchi
or lungs, chronic mucocutaneous herpes simplex virus infection,
Kaposi’s sarcoma, encephalopathy and lymphoma were the WHO
stage 4 conditions with higher incidence in Africa than Asia.
These regional differences in disease specific incidence contin-
ued over time, but by 24–36 months follow-up post ART
initiation, the only differences between regions were for the
WHO stage 3 conditions pulmonary TB, oral candidiasis, weight
loss and chronic diarrhoea which remained higher in Africa than
Asia.
Age Differences in Disease Specific Incidence
In adults and children aged 5–14 years, pulmonary TB had the
highest incidence of all WHO stage 3 or 4 conditions in months 0–
3, with 22.24 (95% CI 21.02, 23.53)and 25.76 (95% CI 20.67,
32.12) episodes per 100 person-years, respectively (Table 6 and
Table 7). The incidence of oral candidiasis, oral leucoplakia and
weight loss greater than 10% of body weight were also high in
adults. In children aged 5–14 years the incidence of oral
candidiasis was highest in months 0–3 with severe bacterial
pneumonia becoming the most common in months 13–24
[incidence 5.07 (95% CI 3.34, 7.69)]. For children ,5 years, oral
candidiasis had the highest incidence in months 0–3 (25.79
episodes per 100 person-years), with pulmonary TB taking
precedence after 12 months ([incidence 4.76 (95% CI 2.38,
9.51) in months 13–24]. Other conditions with high incidence in
children ,5 years were weight loss greater than 10% of body
weight and unexplained chronic diarrhoea for more than month.
Between months 0–3 and months 6–12 on ART the incidence
of pulmonary TB decreased in adults by 78.5% from 22.24 (95%
CI 21.02, 23.53) to 4.78 episodes per 100 person-years (95% CI
4.35, 5.25), and in children aged 5–14 years there was a 77%
reduction from 25.76 (95% CI 20.67, 32.12) to 5.86 episodes per
100 person-years (95% CI 3.59, 9.56). In comparison, for children
,5 years the incidence of pulmonary TB decreased by 48% from
14.33 (95% CI 10.89, 18.85) to 7.45 episodes per 100 person-years
(95% CI 4.23, 13.12). In the period 6–12 months on ART,
bacterial pneumonia was more commonly diagnosed in children
[incidence 6.82 episodes per 100 person-years (95% CI 3.78,
12.33) for those ,5 years and 5.50 episodes per 100 person-years
(95% CI 3.31, 9.12) for those 5–14 years] compared to adults
(incidence 0.94 episodes per 100 person-years (95% CI 0.76, 1.16).
Discussion
We demonstrated a high overall incidence of any WHO stage 3
or 4 condition (40.02 episodes per 100 person-years) in the 3 years
following ART initiation in patients in RLS. In the 3 months
immediately following ART initiation, the incidence of any WHO
stage 3 or 4 condition was nearly 14 times higher than that
reported for a resource-rich setting by the Swiss HIV Cohort
Study (106.5 episodes compared with 7.7 episodes per 100 person-
years) [6]. However, we also showed that there were significant
reductions, particularly in the first 12 months, in the incidence of
new WHO stage 3 or 4 conditions during the first 36 months of
ART. Both stage 3 and 4 conditions reduced in overall incidence
by more than 90% in the first year and reductions in disease
specific incidence rates of the conditions with highest initial
incidence ranged from 82% to 97%. These striking decreases in
Table 2. Disease specific incidence over 36 months for selected WHO Stage 3 conditions.
Disease incidence following initiation of ART (no. of first diagnoses per 100 person-years; 95% CI)
WHO stage 3 conditions
0–3 months
n*=34,749
4–6 months
n*=27,423
7–12 months
n*=25,868
13–24 months
n*=21,731
25–36 months
n*=12,445
Pulmonary tuberculosis 21.96 (20.81, 23.17) 9.29 (8.47, 10.18) 4.86 (4.44, 5.32) 2.74 (2.48, 3.02) 2.75 (2.41, 3.14)
Oral candidiasis 22.07 (20.92, 23.28) 8.99 (8.19, 9.88) 4.16 (3.78, 4.59) 2.20 (1.97, 2.26) 1.92 (1.64, 2.25)
Weight loss .10% of body weight 7.12 (6.49, 7.82) 2.89 (2.45, 3.41) 1.87 (1.62, 2.16) 1.32 (1.14, 1.52) 1.27 (1.05, 1.55)
Unexplained chronic diarrhoea .1
month
5.47 (4.92, 6.09) 2.83 (2.40, 3.34) 1.36 (1.15, 1.62) 0.72 (0.59, 0.87) 0.87 (0.69, 1.10)
Oral hairy leucoplakia 6.74 (6.12, 7.42) 3.51 (3.02, 4.07) 1.18 (0.98, 1.41) 0.70 (0.58, 0.85) 1.09 (0.89, 1.35)
Severe bacterial pneumonia 3.19 (2.78, 3.67) 1.65 (1.33, 2.05) 1.17 (0.97, 1.40) 0.79 (0.66, 0.95) 0.36 (0.25, 0.52)
Other severe bacterial infections
(Pyomyositis)
2.12 (1.79, 2.52) 1.18 (0.91, 1.53) 0.84 (0.67, 1.04) 0.51 (0.41, 0.64) 0.38 (0.26, 0.54)
Unexplained prolonged fever .1
month
3.08 (2.67, 3.55) 1.00 (0.75, 1.32) 0.84 (0.67, 1.04) 0.46 (0.37, 0.59) 0.34 (0.23, 0.49)
Unexplained anaemia/neutropenia/
thrombocytopenia
1.33 (1.07, 1.65) 0.47 (0.31, 0.70) 0.34 (0.24, 0.48) 0.18 (0.13, 0.27) 0.09 (0.04, 0.18)
Acute necrotizing ulcerative
stomatitis/gingivitis/periodontitis
0.4 (0.27, 0.60) 0.24 (0.14, 0.43) 0.12 (0.07, 0.22) 0.05 (0.03, 0.11) 0.09 (0.04, 0.18)
Moderate malnutrition 0.29 (0.18, 0.46) 0.12 (0.05, 0.27) 0.07 (0.03, 0.15) 0.03 (0.01, 0.08) 0.04 (0.01, 0.12)
HIV associated chronic lung disease n/a 0.02 (0.00, 0.14) 0.02 (0.01, 0.08) 0.01 (0.00, 0.05) n/a
Lymphoid interstitial pneumonitis 0.03 (0.01, 0.13) 0.02 (0.00, 0.14) 0.02 (0.01, 0.08) n/a n/a
Lymphnode TB 0.06 (0.02, 0.17) 0.02 (0.00, 0.14) 0.03 (0.01, 0.10) 0.01 (0.00, 0.05) 0.01 (0.00, 0.09)
*n=the number of patients who were followed up for the entire time period indicated.
doi:10.1371/journal.pone.0052019.t002
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Disease incidence following initiation of ART(no. of first diagnoses per 100 person-years; 95% CI)
WHO stage 4 conditions
0–3 months
n*=34,749
4–6 months
n*=27,423
7–12 months
n*=25,868
13–24 months
n*=21,731
25–36 months
n*=12,445
Candidiasis of the oesophagus,
trachea, bronchi or lungs
4.67 (4.16, 5.25) 1.26 (0.98, 1.62) 0.74 (0.59, 0.94) 0.47 (0.37, 0.60) 0.38 (0.26, 0.54)
HIV wasting syndrome 2.64 (2.26, 3.08) 0.83 (0.61, 1.13) 0.47 (0.36, 0.63) 0.27 (0.20, 0.37) 0.16 (0.09, 0.28)
Extra-pulmonary tuberculosis 5.30 (4.75, 5.90) 2.63 (2.21, 3.12) 1.19 (0.99, 1.43) 0.83 (0.69, 0.99) 0.95 (0.76, 1.20)
Herpes simplex virus infection
mucocutaneous .1 month
1.44 (1.17, 1.77) 1.16 (0.89, 1.50) 0.31 (0.22, 0.44) 0.15 (0.10, 0.23) 0.26 (0.17, 0.40)
Kaposi’s sarcoma 1.07 (0.84, 1.36) 0.75 (0.55, 1.04) 0.33 (0.23, 0.47) 0.12 (0.08, 0.19) 0.13 (0.07, 0.23)
Cryptococcosis - extrapulmonary 2.82 (2.43, 3.27) 0.94 (0.70, 1.25) 0.22 (0.14, 0.33) 0.19 (0.13, 0.28) 0.18 (0.10, 0.30)
Pneumocystis jiroveci pneumonia 1.72 (1.42, 2.08) 0.35 (0.21, 0.56) 0.21 (0.13, 0.32) 0.16 (0.10, 0.24) 0.05 (0.02, 0.13)
Toxoplasmosis of the brain 1.47 (1.20, 1.81) 0.83 (0.61, 1.13) 0.18 (0.11, 0.28) 0.15 (0.10, 0.23) 0.06 (0.03, 0.15))
Encephalopathy 0.36 (0.23, 0.54) 0.12 (0.05, 0.27) 0.07 (0.03, 0.15) 0.05 (0.03, 0.11) 0.01 (0.00, 0.09)
Cytomegalovirus disease of an
organ other than liver, spleen or
lymph nodes
0.49 (0.34, 0.69) 0.47 (0.31, 0.70) 0.25 (0.17, 0.37) 0.12 (0.08, 0.19) n/a
Lymphoma 0.13 (0.06, 0.26) 0.06 (0.02, 0.19) 0.03 (0.01, 0.10) 0.03 (0.01, 0.07) n/a
Cryptosporidiosis with diarrhea .1 month 0.16 (0.09, 0.30) 0.02 (0.00, 0.14) 0.02 (0.01, 0.08) 0.01 (0.00, 0.05) 0.03 (0.01, 0.10)
Non TB mycobacterial infection 3.03 (2.63, 3.50) 0.94 (0.70, 1.25) 0.27 (0.18, 0.39) 0.12 (0.08, 0.19) 0.09 (0.04, 0.18)
Any disseminated endemic mycosis 0.49 (0.34, 0.69) 0.20 (0.11, 0.38) 0.09 (0.05, 0.18) 0.02 (0.01, 0.06) 0.03 (0.01, 0.10)
Penicilliosis Marneffei 1.15 (0.91, 1.45) 0.24 (0.14, 0.43) 0.07 (0.03, 0.15) 0.01 (0.00, 0.05) 0.03 (0.01, 0.10)
Isosporidiosis with diarrhea .1 month 0.06 (0.02, 0.17) 0.12 (0.05, 0.27) 0.05 (0.02, 0.12) 0.03 (0.01, 0.08) n/a
Septicaemia recurrent 0.03 (0.01, 0.13) n/a 0.02 (0.01, 0.08) n/a n/a
Cervical carcinoma 0.06 (0.02, 0.17) 0.06 (0.02, 0.19) 0.01 (0.00, 0.07) 0.01 (0.00, 0.05) n/a
HIV associated cardiomyopathy 0.05 (0.02, 0.15) n/a 0.02 (0.01, 0.08) 0.02 (0.01, 0.06) n/a
Visceral leishmaniasis 0.03 (0.01, 0.13) 0.33 (0.20, 0.53) 0.28 (0.19, 0.41) 0.12 (0.07, 0.19) 0.16 (0.09, 0.28)
*n=the number of patients who were followed up for the entire time period indicated.
doi:10.1371/journal.pone.0052019.t003
Table 4. Regional disease specific incidence of WHO stage 3 conditions in months 0–3 following ART initiation.
Africa Asia
WHO stage 3 conditions
Number
of first
diagnoses
Incidence in months 0–3
following initiation of ART
(no. of first diagnoses per
100 person-years; 95% CI)
Number
of first
diagnoses
Incidence in months 0–3
following initiation of ART
(no. of first diagnoses per
100 person-years; 95% CI)
p value
(Africa vs
Asia)
Pulmonary tuberculosis 1073 30.45 (28.68, 32.33) 243 9.90 (8.73, 11.23) ,0.001
Oral candidiasis 1054 29.84 (28.09, 31.70) 253 10.32 (9.12, 11.67) ,0.001
Weight loss .10% of body weight 423 11.78 (10.71, 12.96) 13 0.52 (0.30, 0.90) ,0.001
Unexplained chronic diarrhoea .1 month 308 8.55 (7.64, 9.56) 26 1.05 (0.71, 1.54) ,0.001
Oral hairy leucoplakia 172 4.76 (4.10, 5.53) 231 9.41 (8.27, 10.71) ,0.001
Severe bacterial pneumonia 154 4.26 (3.64, 4.99) 30 1.21 (0.85, 1.73) ,0.001
Other severe bacterial infections
(Pyomyositis)
113 3.12 (2.60, 3.75) 12 0.48 (0.27, 0.85) ,0.001
Unexplained prolonged fever .1 month 105 2.90 (2.40, 3.51) 67 2.70 (2.13, 3.44) 0.677
Unexplained anaemia/neutropenia/
thrombocytopenia
45 1.24 (0.93, 1.66) 7 0.28 (0.13, 0.59) ,0.001
Acute necrotizing ulcerative stomatitis/
gingivitis/periodontitis
23 0.63 (0.42, 0.95) 1 0.04 (0.01, 0.29) 0.003
Moderate malnutrition 17 0.47 (0.29, 0.75) 1 0.04 (0.01, 0.29) 0.002
doi:10.1371/journal.pone.0052019.t004
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Africa Asia
WHO stage 4 conditions
Number
of first
diagnoses
Incidence in months 0–3
following initiation of ART
(no. of first diagnoses per
100 person-years; 95% CI)
Number of
first
diagnoses
Incidence in months 0–3
following initiation of ART
(no. of first diagnoses per
100 person-years; 95% CI)
p value
(Africa vs
Asia)
Candidiasis of the oesophagus, trachea,
bronchi or lungs
208 5.76 (5.03, 6.60) 77 3.11 (2.49, 3.89) ,0.001
HIV wasting syndrome 143 3.95 (3.36, 4.66) 17 0.68 (0.43, 1.10) ,0.001
Extra-pulmonary tuberculosis 123 3.40 (2.85, 4.06) 195 7.92 (6.89, 9.12) ,0.001
Herpes simplex virus infection
mucocutaneous .1 month
79 2.18 (1.75, 2.72) 9 0.36 (0.19, 0.70) ,0.001
Kaposi’s sarcoma 64 1.77 (1.38, 2.26) 2 0.08 (0.02, 0.32) ,0.001
Cryptococcosis - extrapulmonary 63 1.74 (1.36, 2.23) 107 4.33 (3.58, 5.23) ,0.001
Pneumocystis jiroveci pneumonia 48 1.32 (1.00, 1.76) 56 2.26 (1.74, 2.94) 0.006
Toxoplasmosis of the brain 26 0.72 (0.49, 1.05) 63 2.54 (1.99, 3.26) ,0.001
Encephalopathy 19 0.52 (0.33, 0.82) 3 0.12 (0.04, 0.37) 0.010
Cytomegalovirus disease of an organ
other than liver, spleen or lymph nodes
14 0.39 (0.23, 0.65) 16 0.64 (0.40, 1.05) 0.172
Lymphoma 7 0.19 (0.09, 0.40) 1 0.04 (0.01, 0.29) 0.108
Cryptosporidiosis with diarrhea .1 month 5 0.14 (0.06, 0.33) 5 0.20 (0.08, 0.48) 0.571
Non TB mycobacterial infection 3 0.08 (0.03, 0.26) 184 7.47 (6.47, 8.64) ,0.001
Any disseminated endemic mycosis 2 0.06 (0.01, 0.22) 28 1.13 (0.78, 1.64) ,0.001
Penicilliosis Marneffei 0 n/a 71 2.87 (2.27, 3.62) n/a
doi:10.1371/journal.pone.0052019.t005
Table 6. Disease specific Incidence of WHO stage 3 conditions in months 0–3 following ART initiation by age.
WHO stage 3 conditions Age ,5 years Age 5–14 years Age $15 years
Number
of first
diagnoses
Incidence in months
0–3 following initiation
of ART(no. of first
diagnoses per 100
person-years; 95% CI)
Number
of first
diagnoses
Incidence in months
0–3 following initiation
of ART(no. of first
diagnoses per 100
person-years; 95% CI)
Number
of first
diagnoses
Incidence in months
0–3 following initiation
of ART(no. of first
diagnoses per 100
person-years; 95% CI)
Pulmonary tuberculosis 51 14.33 (10.89, 18.85) 79 25.76 (20.67, 32.12) 1199 22.24 (21.02, 23.53)
Oral candidiasis 91 25.79 (21.00, 31.67) 49 15.82 (11.95, 20.91) 1197 22.19 (20.96, 23.48)
Oral hairy leucoplakia 5 1.39 (0.58, 3.33) 8 2.55 (1.28, 5.11) 401 7.33 (6.64, 8.08)
Weight loss .10% of body weight 36 10.06 (7.26, 13.95) 14 4.48 (2.65, 7.56) 388 7.08 (6.41, 7.82)
Unexplained chronic diarrhoea .1
month
22 6.12 (4.03, 9.29) 19 6.08 (3.88, 9.53) 296 5.40 (4.81, 6.05)
Unexplained prolonged fever .1
month
5 1.39 (0.58, 3.33) 11 3.52 (1.95, 6.35) 174 3.17 (2.73, 3.67)
Severe bacterial pneumonia 19 5.29 (3.37, 8.29) 24 7.71 (5.16, 11.50) 154 2.80 (2.39, 3.28)
Other severe bacterial infections
(Pyomyositis)
6 1.67 (0.75, 3.71) 9 2.88 (1.50, 5.53) 116 2.11 (1.76, 2.53)
Unexplained anaemia/neutropenia/
thrombocytopenia
3 0.83 (0.27, 2.58) 6 1.92 (0.86, 4.26) 73 1.33 (1.05, 1.67)
Acute necrotizing ulcerative
stomatitis/gingivitis/periodontitis
2 0.55 (0.14, 2.21) 2 0.64 (0.16, 2.55) 21 0.38 (0.25, 0.58)
HIV associated chronic lung disease 0 n/a 0 n/a 0 n/a
Lymphoid interstitial pneumonitis 0 n/a 2 0.64 (0.16, 2.55) 0 n/a
Lymphnode TB 1 0.28 (0.04, 1.97) 3 0.96 (0.31, 2.97) n/a n/a
Moderate malnutrition 13 3.62 (2.10, 6.23) 5 1.60 (0.66, 3.83) n/a n/a
doi:10.1371/journal.pone.0052019.t006
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observed in patients on ART in high income countries [6,9,13]. As
our analyses are not adjusted for death and loss to follow-up in the
cohort, the absolute reductions in incidence rates cannot be
ascribed to the beneficial effects of ART alone [14]. Nevertheless it
is known that the immune restorative effects of ART reduce the
incidence of new or recurrent WHO stage 3 and 4 conditions
[6,7,8,9] and it is likely that ART has played a significant role in
their reductions in our cohort. This emphasizes the importance of
access to early ART initiation for those eligible to reduce the
impact of HIV related conditions during early ART in RLS. This
requires increased efforts to enable early diagnosis and accurate
clinical and immunological staging of HIV infected patients, and
their rapid access to effective, non-toxic, free and sustained ART
in these settings.
The considerable incidence of HIV associated clinical condi-
tions during early ART also emphasizes the importance of
increased disease prevention efforts prior to ART commencement.
Such interventions include isoniazid chemophrophylaxis for TB
[15,16], fluconazole prophylaxis for those who are cryptococcal
antigen negative and have delays in ART initiation [17,18] and
cotrimoxazole therapy for PCP, toxoplasmosis, bacterial sepsis and
malaria [19,20]. Resources and improved tools are also required
to facilitate early and improved diagnosis of opportunistic
infections, as well as effective, adapted and affordable treatments
to minimize their impact on morbidity and mortality.
We defined the burden of different WHO stage 3 and 4
conditions stratified by age and region. This provides information
for clinicians to use in determining which conditions to focus on
for prevention, early diagnosis and treatment. It is also vital
information for programme planners to guide allocation of
resources required for disease management in patients on ART,
and for strategic planning and resource prioritization. For
example, age-specific and regional incidence rates of TB in
patients on ART can aid strategic decision making about which
patient populations to prioritise in implementing isoniazid
preventive therapy (IPT) if universal IPT is not chosen or possible.
Also, knowing specific disease incidences can aid in decision
making about programme drug formularies.
TB and candidiasis were the most common conditions seen in
our RLS cohort. TB is a leading cause of disease in HIV infected
patients and is the leading cause of HIV-related deaths [2,17,21].
Our results re-affirm the importance of TB as a pathogen in HIV
infected patients treated with ART. Importantly, our results
support other studies in suggesting that ART alone reduces the
incidence of TB [22,23,24]. Provision of IPT can further reduce
Table 7. Disease specific Incidence of WHO stage 4 conditions in months 0–3 following ART initiation by age.
WHO stage 4 conditions Age ,5 years Age 5–14 years Age $15 years
Number
of first
diagnoses
Incidence in months
0–3 after initiation of
ART(no. of first
diagnoses per 100
person-years; 95% CI)
Number
of first
diagnoses
Incidence in months
0–3 after initiation
of ART(no. of first
diagnoses per 100
person-years; 95% CI)
Number
of first
diagnoses
Incidence in months
0–3 after initiation of
ART(no. of first
diagnoses per 100
person-years; 95% CI)
Extra-pulmonary tuberculosis 2 0.55 (0.14, 2.21) 6 1.92 (0.86, 4.26) 318 5.80 (5.20, 6.48)
Candidiasis of the oesophagus,
trachea, bronchi or lungs
4 1.11 (0.42, 2.96) 7 2.23 (1.06, 4.68) 277 5.05 (4.49, 5.68)
Non TB mycobacterial infection 3 0.83 (0.27, 2.58) 4 1.28 (0.48, 3.40) 180 3.28 (2.83, 3.79)
Cryptococcosis 1 0.28 (0.04, 1.97) 0 n/a 173 3.15 (2.71, 3.65)
HIV wasting syndrome 19 5.29 (3.37, 8.29) 8 2.55 (1.28, 5.11) 136 2.47 (2.09, 2.92)
Pneumocystis jiroveci pneumonia 7 1.94 (0.93, 4.08) 6 1.92 (0.86, 4.26) 93 1.69 (1.38, 2.07)
Toxoplasmosis of the brain 0 n/a 1 0.32 (0.04, 2.26) 90 1.64 (1.33, 2.01)
Herpes simplex virus infection
mucocutaneous .1 month
0 n/a 4 1.28 (0.48, 3.40) 85 1.54 (1.25, 1.91)
Penicilliosis Marneffei 0 n/a 3 0.96 (0.31, 2.97) 68 1.24 (0.97, 1.57)
Kaposi’s sarcoma 0 n/a 1 0.32 (0.04, 2.26) 65 1.18 (0.93, 1.50)
Cytomegalovirus disease of an organ other
than liver, spleen or lymph nodes
2 0.55 (0.14, 2.21) 1 0.32 (0.04, 2.26) 27 0.49 (0.34, 0.71)
Any disseminated endemic mycosis 2 0.55 (0.14, 2.21) 2 0.64 (0.16, 2.55) 26 0.47 (0.32, 0.69)
Encephalopathy 0 n/a 2 0.64 (0.16, 2.55) 20 0.36 (0.23, 0.56)
Cryptosporidiosis with diarrhea .1 month 0 n/a 1 0.32 (0.04, 2.26) 9 0.16 (0.08, 0.31)
Lymphoma 1 0.28 (0.04, 1.97) 0 n/a 7 0.13 (0.06, 0.27)
Isosporidiosis with diarrhea .1 month 0 n/a 0 n/a 4 0.07 (0.03, 0.19)
Cervical carcinoma 0 n/a 0 n/a 4 0.07 (0.03, 0.19)
Septicaemia recurrent 0 n/a 0 n/a 2 0.04 (0.01, 0.15)
Visceral leishmaniasis 0 n/a 0 n/a 2 0.04 (0.01, 0.15)
HIV associated cardiomyopathy 0 n/a 1 0.32 (0.04, 2.26) 2 0.04 (0.01, 0.15)
HIV associated nephropathy 0 n/a 0 n/a 0 n/a
Progressive multifocal leucoencephalopathy 0 n/a 0 n/a 0 n/a
doi:10.1371/journal.pone.0052019.t007
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recommended [16]. Likewise our study showed ART is associated
with a reduction in the incidence of candidiasis. Although a recent
study from Uganda showed that giving fluconazole prophylaxis to
those with a CD4 count ,200 cells/mm
3 can further reduce the
impact of candidiasis both pre and post ART [17], it did not
reduce overall mortality, and is currently not recommended by
WHO [18]. Important contributions to the disease burden in our
study were also made by potentially preventable stage 4 conditions
such as non-tuberculous mycobacteria, cryptococcosis, pneumo-
cystis and toxoplasmosis. The most common conditions differed
from those in a resource rich setting where the oseophageal
candidiasis, PCP and cytomegalovirus disease were the most
frequently reported conditions during the first 6 months of ART
[6].
There were important regional differences in the overall and
disease specific incidences of any stage 3 and 4 condition following
ART initiation. The incidence of any stage 3 HIV associated
condition was almost 4 times higher in Africa than Asia despite
African patients being less immunosuppressed overall at baseline.
This may be due to increased exposure to the relevant pathogens
in Africa or less likely, to improved diagnosis in Africa [22,26].
Some individual stage 4 conditions were more common in Asian
programmes, particularly in the first 3 months after ART
initiation, likely due to the higher rate of immunosuppression of
these patients at baseline, and differential prevalence of specific
pathogens. For example, penicilliosis is not endemic in Africa.
The incidence of any first stage 3 condition did not differ by age
however there were important differences in the incidence of
individual conditions by age. Pulmonary TB was diagnosed less
commonly in children ,5 years, although this may be underes-
timated given the difficulty of diagnosis in this age-group.
Additionally, severe bacterial pneumonia was more common in
children ,15 years compared with adults.
There were significant age-related differences in the overall
incidences of stage 4 conditions that may be explained by the
relative level of baseline immunodeficiency. HIV-infected children
,5 years usually have rapidly progressive disease with high
mortality [27]. This increased immunodeficiency may explain the
higher incidence of stage 4 conditions in this age-group.
Conversely, many children in the 5–14 age-group will have been
infected peripartum, but survived due to less rapidly progressive
disease. This may explain this group’s low incidence of stage 4
conditions. In addition, there were more differences seen in the
incidence of specific stage 4 conditions between children ,5 years
and adults. Children ,5 years were more likely to have HIV
wasting compared with adults but less likely to have all other
conditions except pneumocystis pneumonia. There were no cases
of toxoplasmosis, penicilliosis or Kaposi’s sarcoma in patients ,5
years of age. As reported previously [28,29], crytptococcosis was
rare under 15 years of age (1 case), supporting recent WHO
guidelines recommending against screening and pre-emptive
treatment in children due to low prevalence [18].
Information about age-specific incidence rates of various
conditions during ART may have important practical applica-
tions. For example, TB incidence reduced by 48% during the first
12 months of ART in children ,5 years which was less than the
79% reduction in adults and 77% reduction in children 5–14
years. This suggests IPT may have relatively greater additional
impact in children ,5 years than older age-groups during early
ART. In addition, the incidence of bacterial pneumonia during
the first 12 months of ART was up to 7 times higher in children
than adults, supporting particular attention being paid to the
prevention, diagnosis and treatment of this condition in children.
This study has a number of limitations. Firstly, reliance on basic
investigations to support clinical assessment in the diagnosis of
HIV associated conditions may have resulted in diagnostic
inaccuracies. For example TB in children ,5 years old is difficult
to confirm with AFB stains alone, and reliance on clinical
assessment may have under or overestimated its true incidence. In
addition, clinician practices and availability of investigations may
have varied between programmes, influencing the relative
frequencies of diagnoses. Nevertheless, the results of this study
remain relevant because the diagnoses reflect the reality of clinical
practice in most RLS where ART is delivered and involves a large
cohort of patients. Secondly, the lack of pre-ART data precluded
the comparison of incidence rates before and after ART. Thirdly,
the Asian data was predominantly from Myanmar programmes so
results may not be generalisable across all Asian programmes.
Fourthly, we cannot judge the extent to which declining incidence
rates are due to ART and care effects; some of these declines may
be due to deaths of severely ill persons in the prior time periods.
Finally, we were unable to ascertain whether patients lost to
follow-up developed any HIV related conditions. Furthermore, as
inclusion criteria required at least 3 months of follow-up on ART,
patients developing stage 3 and 4 conditions in the first 3 months,
which may have increased their risk of lost-to follow-up, could
have led to an underestimation of incidence rates in this initial
period.
Conclusion
In RLS the incidence of WHO stage 3 and 4 conditions in the
early period following ART initiation is high when compared to
similar studies in resource-rich settings. However, with early
deaths of the sickest patients and with the benefits of ART for the
remaining patients, the incidence of HIV associated conditions
greatly reduces with time on ART, particularly within the first 12
months. TB and candidiasis account for the greatest disease
burden, but many other potentially preventable diseases are also
important. Efforts directed towards prevention, early diagnosis
and effective treatment of these conditions before and during
ART, and the early and accurate assessment for, and initiation of,
ART in eligible patients, are important to reduce morbidity during
ART in RLS.
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